证券之星消息，截至2025年8月21日收盘，美好医疗(301363)报收于23.4元，上涨18.0%，换手率 33.93%，成交量53.02万手，成交额11.82亿元。 | 日期 | | | | | 收盘价 涨跌幅 主力净流入 主力净占比 游资净点比 散户净流入 散户净占比 | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 2025-08-21 | 23.40 18.00% | | 9006.44万 | 7.62% | -1.13亿 | -9.56% | 2297.20万 | 1.94% | | 2025-08-20 | 19.83 | -1.69% | -1545.21万 | -5.48% | 798.42万 | 2.83% | 746.79万 | 2.65% | | 2025-08-19 | 20.17 | -1.90% | -733.41万 | -2.27% | -2009.05万 | -6.23% | 2742.46万 | 8.50% | | 2025-08-18 | 20.56 | -0.77% | -2337.24万 ...

（编辑 袁冠琳） 证券日报网讯 美好医疗8月21日在互动平台回答投资者提问时表示，2025年5月23日，公司分别召开第 二届董事会第十八次会议和第二届监事会第十五次会议，审议通过《关于向激励对象首次授予限制性股 票的议案》。 ...

Core Viewpoint - The company reported a slight decline in revenue from home respiratory device components and cochlear implant components for the first half of 2025, while showing significant growth in new business areas [1] Group 1: Revenue Performance - Revenue from home and consumer electronics components increased by 35.69% year-on-year [1] - Revenue from other medical product components grew by 54.41% year-on-year [1] Group 2: Strategic Initiatives - The company plans to continue systematic advancement in technology, business expansion, and talent development to establish a solid foundation for long-term high-quality sustainable growth [1]

Group 1 - The company emphasizes that robotics is a significant direction for future industrial development, with a broad market space [2] - The company's household and consumer electronics division is actively exploring the development path of humanoid robots, leveraging existing PEEK manufacturing technology, precision mold technology, and sensor technology [2] - The company has established mature PEEK manufacturing and molding technology, with current PEEK products including cochlear implant bodies, PEEK surgical fixation plates in craniofacial repair systems, and Class III implantable hemostatic clips [2]

Group 1 - The company, Meihao Medical, is collaborating with well-known domestic and international surgical robot companies on components for vascular interventional surgical robots, joint surgical robots, and bronchial natural orifice (LON) robots, which are at different stages of cooperation [2] - The revenue scale of related products is currently small, indicating a nascent market presence [2]

Core Viewpoint - Meihua Medical (301363) has seen significant trading activity, with a daily increase of 18.0% on August 21, 2025, marking its first appearance on the "Dragon and Tiger List" in the past five trading days [1] Trading Data Summary - As of the close on August 21, 2025, Meihua Medical's stock price was 23.4 yuan, with a turnover rate of 33.93% and a trading volume of 530,200 lots, resulting in a total transaction value of 1.182 billion yuan [1] - Institutional investors collectively sold 31.6622 million yuan worth of shares, while northbound funds recorded a net purchase of 47.8319 million yuan [1] - The top five trading seats included significant contributions from institutional and northbound funds, with the "Deep Stock Connect" seat showing a net purchase of 47.8319 million yuan [2] Institutional Activity - The trading data indicates that institutional investors had a mixed activity, with some seats showing significant net selling, while others, particularly the "Deep Stock Connect" seat, demonstrated strong buying interest [3] - The total buying amount from the top trading seats reached 193.4836 million yuan, while the total selling amount was 33.0937 million yuan, resulting in a net buying of 160.3898 million yuan [2]

Group 1 - The core viewpoint of the article highlights that Meihao Medical's H1 2025 net profit attributable to the parent company is 110 million yuan, a year-on-year decrease of 32.4% [1] - The company's core business revenue from home respiratory machine components is 440 million yuan, down 2.8% year-on-year, while revenue from cochlear implant components is 60 million yuan, down 7.5% year-on-year [1] - The underperformance is attributed to geopolitical tensions affecting the construction and production timeline of the company's Malaysian Phase III industrial base, impacting the delivery rhythm of core business orders [1] Group 2 - Despite the short-term challenges, the company has strong respiratory and cochlear implant businesses, with a continuously enriching product pipeline and ongoing development of new businesses and customers, indicating broad long-term potential [1] - Based on comparable companies' average valuation for 2025, the company is given a 36 times price-to-earnings ratio, corresponding to a target price of 24.48 yuan, maintaining a "buy" rating [1]

Market Overview - The Shanghai Composite Index closed at 3771.10 points, above the annual line, with a change of 0.13% [1] - The total trading volume of A-shares reached 24603.35 billion yuan [1] Stocks Breaking Annual Line - A total of 28 A-shares have surpassed the annual line today, with notable stocks including: - Meihua Medical (301363) with a deviation rate of 14.81% and a daily increase of 18.00% [1] - Meirui New Materials (300848) with a deviation rate of 4.67% and a daily increase of 5.49% [1] - Kangle Health (833575) with a deviation rate of 4.29% and a daily increase of 4.40% [1] Stocks with Smaller Deviation Rates - Stocks that have just crossed the annual line with smaller deviation rates include: - Guotou Power (600886) with a deviation rate of 0.01% and a daily increase of 1.30% [2] - Shanghai Pharmaceuticals (601607) with a deviation rate of 0.08% and a daily increase of 0.95% [2] - *ST Jinglun (600355) with a deviation rate of 0.20% and a daily increase of 0.86% [2]

（原标题：美好医疗龙虎榜数据（8月21日）） 美好医疗今日上涨18.00%，全天换手率33.93%，成交额11.82亿元，振幅19.05%。龙虎榜数据显示，机 构净卖出3166.22万元，深股通净买入4783.19万元，营业部席位合计净买入1004.13万元。 深交所公开信息显示，当日该股因日收盘价涨幅达18.00%上榜，机构专用席位净卖出3166.22万元，深 股通净买入4783.19万元。 证券时报•数据宝统计显示，上榜的前五大买卖营业部合计成交3.61亿元，其中，买入成交额为1.93亿 元，卖出成交额为1.67亿元，合计净买入2621.10万元。 具体来看，今日上榜的营业部中，共有4家机构专用席位现身，即买三、买五、卖一、卖二，合计买入 金额5030.49万元，卖出金额8196.71万元，合计净卖出3166.22万元，深股通为第一大买入营业部及第三 大卖出营业部，买入金额为8064.40万元，卖出金额为3281.22万元，合计净买入4783.19万元。 资金流向方面，今日该股主力资金净流入8741.15万元，其中，特大单净流入7184.94万元，大单资金净 流入1556.20万元。近5日主力资金净流入4 ...

Market Overview - On August 21, the medical device sector rose by 1.02% compared to the previous trading day, with Meihao Medical leading the gains [1] - The Shanghai Composite Index closed at 3771.1, up 0.13%, while the Shenzhen Component Index closed at 11919.76, down 0.06% [1] Top Performers - Meihao Medical (301363) closed at 23.40, up 18.00% with a trading volume of 530,200 shares and a transaction value of 1.182 billion [1] - Haooubo (688656) closed at 125.62, up 8.42% with a trading volume of 32,300 shares and a transaction value of 403 million [1] - Rejing Bio (688068) closed at 237.62, up 6.80% with a trading volume of 25,200 shares and a transaction value of 588 million [1] Underperformers - Sainuo Medical (688108) closed at 34.22, down 8.21% with a trading volume of 790,800 shares and a transaction value of 273.7 million [2] - Linoyoubao (301188) closed at 19.86, down 6.23% with a trading volume of 296,400 shares and a transaction value of 596 million [2] - Shangrong Medical (002551) closed at 4.68, down 5.45% with a trading volume of 975,900 shares and a transaction value of 464 million [2] Capital Flow - The medical device sector experienced a net outflow of 766 million from institutional investors, while retail investors saw a net inflow of 903 million [2][3] - Major stocks like Meihao Medical and Mindray Medical (300760) had significant net inflows from retail investors, indicating strong retail interest despite overall institutional outflows [3]